



**Media Releases » Torrent Pharma records 21% revenue growth in Q3 FY12;
declares 120% Interim Dividend**
January 23rd, 2012

Ahmedabad-based Torrent Pharmaceuticals Limited, today released its financial results for the third quarter ended 31st December, 2011. The Q3 revenues stood at Rs. 697 crores, up by 21% from Rs. 578 crores in the comparable quarter of last year. The Company declared an Interim Dividend of Rs. 6 per share.

During Q3, domestic formulation business recorded revenues of Rs. 229 crores, growing by 8% mainly due to a relatively low performance in the acute therapy segment. International revenues grew by 33% to Rs. 394 crores. Operations in Brazil registered revenue growth of 27% while the Germany-based Heumann registered a revenue growth of 14%. Revenues from the US operations grew by 67% while business from Europe (other than Heumann), Russia & CIS and Rest of the World recorded a growth of 37%.

Operating profits (PBDIT) for the quarter stood at Rs. 121 crores showing a growth of 6%. Net profit for the quarter grew by 8% to Rs. 83 crores compared to Rs. 77 crores during the same period last year.

For YTD Dec. 2011, the revenues increased by 19% to Rs. 2,027 crores compared with Rs. 1,700 crores for the corresponding period last year. For YTD Dec. 2011, the PBDIT grew by 20% to Rs. 415 crores while the Net Profit, grew by 26% to Rs. 286 crores.

Investments in product development are being made to support the build-up of the Brazil, Europe and US operations. The total revenue expenditure on R&D was 5% of Q3 2011-12 consolidated net sales and operating income.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs. 2,200 crores is the flagship company of the Torrent Group. With many of its products ranking among the Top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 702 scientists in the areas of drug discovery and development. Currently, Torrent has various discovery projects in pipeline. It has filed 445 patents for NCE's in all major markets worldwide, of which 207 patents have been granted so far. Torrent's manufacturing plant at Chhatral has a capacity to manufacture approx. 5,500 million tablets, capsules and vials and 60,000 kgs. of Bulk Drugs/API. The facility has already been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 5,000 million tablets, 500 million capsules and 1 million Oral Liquid bottles per annum. The Company recently commissioned a new manufacturing plant at Sikkim having capacity to manufacture 3,900 million tablets per annum.

